SYN - Synthetic Biologics, Inc.
| Previous Close | 0.3979 |
| Open | 0.4000 |
| Bid | 0.3972 x 800 |
| Ask | 0.4094 x 3200 |
| Day's Range | 0.3902 - 0.4095 |
| 52 Week Range | 0.3700 - 0.9300 |
| Volume | 47,175 |
| Avg. Volume | 86,210 |
| Market Cap | 6.706M |
| Beta (3Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1230 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.25 |
- PR Newswire
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office (USPTO) has granted a U.S. patent and issued a Notice of Allowance for a patent application covering various aspects of the clinical SYN-010 program. Recently granted U.S. Patent No. 10,328,151, which is co-owned by Synthetic Biologics and Cedars-Sinai Medical Center (CSMC) and exclusively licensed to Synthetic Biologics, covers the composition of matter of the SYN-010 clinical agent.
- Simply Wall St.
Does The Synthetic Biologics, Inc. (NYSEMKT:SYN) Share Price Tend To Follow The Market?
If you own shares in Synthetic Biologics, Inc. (NYSEMKT:SYN) then it's worth thinking about how it contributes to the...
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 Synthetic Biologics Inc Earnings Call
- GlobeNewswire
Sýn hf.: Financial results below expectations but positive outlook
Sýn´s Q2 2019 financial statement was approved by Sýn´s CEO and Board of Directors at a board meeting on August 28, 2019. At the beginning of the year, the accounting treatment of broadcasting license rights was changed. Broadcasting license rights was classified as inventory but as of January 1, 2019, it is classified as intangible assets.
- GlobeNewswire
Sýn hf.: Change in guidance
After changes in management, which occurred in the first half of the year, a new financial forecast has been implemented. The forecasted EBITDA will be lowered since revenues in telecom and media are forecasted close to 400 million lower and cost of media content and distribution are estimated 160 million higher. The previous forecast for free cash flow is unchanged but it is clear the result will be at the lower end of the 1,6-2,0 bn range. Management has made changes to the financial reporting process of each division and strengthen its key control procedures, which will lead to better forecasting going forward. Measures taken this summer, which will be realized at the end of the year, have lowered the cost basis of the company.
- PR Newswire
Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results
-- Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b /2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients ...
- PR Newswire
Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019
-- Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET -- ROCKVILLE, Md. , Aug. 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- PR Newswire
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards
ROCKVILLE, Md., July 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today receipt, on June 28, 2019, of notification from the NYSE American LLC (the "Exchange") that the Company has regained compliance with Part 10, Section 1003 of the NYSE American's Company Guide (the "Company Guide") relating to the Exchange's continued listing requirements. The Company previously received notification from the NYSE American citing failure to comply with the minimum stockholders' equity continued listing standard as set forth in Part 10, Section 1003 of the Company Guide.
- Simply Wall St.
Those Who Purchased Synthetic Biologics (NYSEMKT:SYN) Shares Three Years Ago Have A 99% Loss To Show For It
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...
- GlobeNewswire
Sýn hf.: Notification of related party trading
See attachment: Attachment NOMX - Viðskipti fjárhagslega tengds aðila 24 05 2019
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Synthetic Biologics Inc Earnings Call
- Associated Press
Synthetic Biologics: 1Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 25 cents. In the final minutes of trading on Wednesday, the company's shares hit 61 cents. A year ago, they were trading ...
- PR Newswire
Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results
-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Today, May 8, 2019, ...
- PR Newswire
Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019
-- Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET -- ROCKVILLE, Md. , April 30, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Synthetic Biologics Inc Earnings Call
- PR Newswire
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results
-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Wednesday, February ...
- GlobeNewswire
Sýn hf. : Q4 Investors presentation
See attached: Investors presentation Q4 This announcement is distributed by West Corporation on behalf of West Corporation clients. The issuer of this announcement warrants that they are solely responsible ...
- GlobeNewswire
Sýn hf. : Changes in management of Sýn hf.
Stefán Sigurðsson, the CEO of Sýn hf., has in accordance with an agreement with the Board of Directors, requested to resign from his post, effective as of June 1st 2019. The Board of Directors has requested the Chairman of the Board to take on an active role as regards the organizational structure of the Company as well as ensuring that the operation of the Company will be in good order until a new CEO has been recruited. This announcement is distributed by West Corporation on behalf of West Corporation clients.
- GlobeNewswire
Sýn hf. : Merged company completes its first full year under challenging market conditions
Sýn`s 2018 annual financial statement was approved by Sýn`s CEO and board of directors at a board meeting 27th of February 2019. In December 2017 the company purchased certain assets and operations of 365 Miðlar hf., and this influences the comparison between periods. Sýn and the Faroese company Tjaldur have agreed on heads of terms in the merger of P/F Hey a subsidiary of Sýn and the Faroese IT company Nema a subsidiary of Tjaldur.
- GlobeNewswire
Sýn hf. : Sýn finalizes the merger of Hey P/F with Nema P/F
Reference is made to Stock Exchange announcement from November 1st 2018, according to which Sýn and the Faroese company Tjaldur had agreed heads of terms in relation to a merger of Hey, a subsidiary of Sýn, and the Faroese IT company Nema, a subsidiary of Tjaldur. This announcement is distributed by West Corporation on behalf of West Corporation clients.
- PR Newswire
Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019
-- Conference Call Scheduled for Wednesday, February 27, 2019 at 4:30 p.m. EST -- ROCKVILLE, Md. , Feb. 19, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- PR Newswire
Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored
ROCKVILLE, Md., Jan. 3, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that the first two patients have been enrolled in SYN-010's Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin lactone designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). Cedars-Sinai Medical Center (CSMC) and Synthetic Biologics are co-funding the study, which will further assess the efficacy and safety of SYN-010 in patients diagnosed with IBS-C.
- Thomson Reuters StreetEvents
Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Synthetic Biologics Inc Earnings Call
- GlobeNewswire
Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented, “Over the course of his career, Evan has played key roles in successfully leading companies in the full range of strategic options in financing including private equity and public offerings.
- GlobeNewswire
Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
